

CITATION REPORT

List of articles citing

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

DOI: 10.1053/j.gastro.2014.04.046

Gastroenterology, 2014, 147, 377-84.e1.

Source: <https://exaly.com/paper-pdf/59666284/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
242	Nonalcoholic fatty liver disease. 2015 , 1, 15080		366
241	Nonalcoholic fatty liver disease: new treatments. 2015 , 31, 175-83		65
240	Dietary approach in the treatment of nonalcoholic fatty liver disease. 2015 , 7, 2522-34		29
239	Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice. 2015 , 10, e0121528		25
238	Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. 2015 , 21, 10621-35		30
237	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2015 , 21, 3777-85		82
236	Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. <i>Hepatology</i> , 2015 , 61, 1565-78	11.2	141
235	[Primary liver tumors. Preoperative conditioning of the liver and perioperative management in extended liver resection]. 2015 , 86, 125-31		3
234	Management and diagnosis of fatty liver disease. 2015 , 9, 671-83		7
233	Resolvin E1 and chemerin C15 peptide do not improve rodent non-alcoholic steatohepatitis. 2015 , 98, 295-9		11
232	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015 , 62, S65-75	13.4	185
231	The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?. 2015 , 166, 1335-7		4
230	Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. 2015 , 38, 1228-37		46
229	Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. 2015 , 35, 318-37		19
228	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. 2015 , 35, 338-48		21
227	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. 2015 , 75, 1373-92		50
226	Nonalcoholic fatty liver disease - current status and future directions. 2015 , 16, 541-57		61

225	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. 2015 , 47, 997-1006	279
224	Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr ^{-/-} mice by targeting the TGFβ ¹ /Smad3 pathway. 2015 , 56, 1936-46	29
223	Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. <i>Journal of Hepatology</i> , 2015 , 63, 1476-83	13.4 66
222	Potential for dietary ω fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. 2015 , 6, 694-702	49
221	Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. <i>Journal of Hepatology</i> , 2015 , 62, 190-7	13.4 142
220	Liver biopsy for the selection of patients with nonalcoholic steatohepatitis for clinical trials. <i>Gastroenterology</i> , 2015 , 148, 262	13.3 3
219	Reply: To PMID 24837306. <i>Gastroenterology</i> , 2015 , 148, 261-2	13.3
218	Reply: To PMID 24818764. <i>Gastroenterology</i> , 2015 , 148, 262-3	13.3 2
217	Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2016 , 2016, 1459790	52
216	Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals. 2016 , 17,	8
215	Current management of non-alcoholic fatty liver disease. 2016 , 62, 872-878	7
214	Nonalcoholic Fatty Liver Disease and Steatohepatitis. 2016 , 321-332	
213	Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. 2016 , 17, 1273-1288	10
212	Diabetes and Non-Alcoholic Fatty Liver Disease. 2016 , 745-758	
211	Antifibrotics in chronic liver disease: tractable targets and translational challenges. 2016 , 1, 328-340	22
210	Rôles de l'intestin et du foie dans la progression de la stéatopathie métabolique et sa modulation par les acides gras polyinsaturés à longue chaîne n-3. 2016 , 51, 283-295	
209	Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. 2016 , 61, 1375-86	60
208	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016 , 59, 1121-40	275

207	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 1388-402	13.4	2065
206	Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial. 2016 , 9, 152-61		9
205	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. 2016 , 9, 65-90		197
204	Future Treatments of NASH. 2016 , 15, 125-133		2
203	Pediatric Non-alcoholic Fatty Liver Disease. 2016 , 18, 24		26
202	Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. 2016 , 9, 392-407		73
201	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. 2016 , 2, 9		35
200	Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans. 2016 , 14, 417-430		18
199	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. 2016 , 1, 56-67		103
198	Treatment of Non-Alcoholic Fatty Liver Disease. 2016 , 34 Suppl 1, 27-31		17
197	[A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis]. 2016 , 136, 583-9		3
196	Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1168-1182	6.1	28
195	Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. 2016 , 95, e4529		39
194	Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. 2016 , 60, 147-59		24
193	Pharmacological management of nonalcoholic fatty liver disease. 2016 , 65, 1183-95		70
192	Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. 2016 , 35, 578-86		65
191	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. 2016 , 78, 181-205		212
190	Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016 ,		3

189	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016 , 150, 1798-810	13.3	84
188	Entering the GOLDEN Age for Therapies in NASH. <i>Gastroenterology</i> , 2016 , 150, 1073-1076	13.3	3
187	Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. 2016 , 65, 1049-61		228
186	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. 2016 , 65, 1161-71		43
185	Management of NAFLD: a stage-based approach. 2016 , 13, 196-205		195
184	Emerging Therapies for Nonalcoholic Fatty Liver Disease. 2016 , 20, 365-85		6
183	Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. 2016 , 61, 1387-97		25
182	Perspectives on Treatment for Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2016 , 150, 1835-48	13.3	55
181	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. 2016 , 313-337		
180	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. 2016 , 20, 293-312		135
179	Exercise and diet in the management of nonalcoholic fatty liver disease. 2016 , 65, 1172-82		37
178	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. 2016 , 53, 106-20		28
177	Hyaluronic acid as a non-invasive biomarker of liver fibrosis. 2016 , 49, 302-15		60
176	Current and future treatment options in non-alcoholic steatohepatitis (NASH). 2017 , 11, 357-369		26
175	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. 2017 , 13, 297-310		146
174	Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. 2017 , 46, 217-231		14
173	Treatment of NAFLD with diet, physical activity and exercise. <i>Journal of Hepatology</i> , 2017 , 67, 829-846	13.4	492
172	Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. 2017 , 6, e15		7

171	The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. 2017 , 37, 936-949	117
170	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	
169	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. 2017 , 16, 903-913	18
168	Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. 2017 , 37, 1065-1073	103
167	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	6
166	The therapeutic landscape of non-alcoholic steatohepatitis. 2017 , 37, 634-647	26
165	Nonalcoholic Fatty Liver Disease. 2017 , 867-908	1
164	Therapies for non-alcoholic steatohepatitis. 2017 , 1, 214-220	1
163	DHA increases adiponectin expression more effectively than EPA at relative low concentrations by regulating PPAR α and its phosphorylation at Ser273 in 3T3-L1 adipocytes. 2017 , 14, 52	24
162	Does Nutrition Matter in Liver Disease?. 2017 , 743-759	2
161	Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. 2017 , 9,	54
160	Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. 2017 , 9,	35
159	Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?. 2018 , 63, 1726-1736	5
158	The potential role of statins in treating liver disease. 2018 , 12, 331-339	10
157	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. 2018 , 13, 321-350	234
156	Future therapy for non-alcoholic fatty liver disease. 2018 , 38 Suppl 1, 56-63	33
155	Current and future pharmacological therapies for NAFLD/NASH. 2018 , 53, 362-376	306
154	Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. 2018 , 3, 66-72	21

153	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. 2018 , 15, 425-439		114
152	Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. 2018 , 11, 87-91		9
151	WITHDRAWN: Nonalcoholic steatohepatitis therapies. 2018 ,		
150	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. 2018 , 64, 135-146		61
149	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142		
148	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. 2018 , 37, 37-55		66
147	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. 2018 , 181, 108-125		64
146	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018 , 67, 328-357	11.2	2641
145	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. 2018 , 33, 86-98		71
144	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2018 , 22, 189-199		19
143	Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight. 2018 , 37, 1474-1484		37
142	New therapeutic perspectives in non-alcoholic steatohepatitis. 2018 , 41, 128-142		8
141	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. 2018 , 1864, 607-617		26
140	DHA supplementation prevent the progression of NASH via GPR120 signaling. 2018 , 820, 31-38		20
139	The nutritional geometry of liver disease including non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018 , 68, 316-325	13.4	19
138	Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. 2018 , 183, 177-204		108
137	Lipotoxicity and the gut-liver axis in NASH pathogenesis. <i>Journal of Hepatology</i> , 2018 , 68, 280-295	13.4	324
136	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 11, CD003177		89

135	Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. 2018 , 97, e12271	55
134	Managing diabetes and liver disease association. 2018 , 19, 166-179	11
133	Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. 2018 , 9, 2418	23
132	Effective Food Ingredients for Fatty Liver: Soy Protein EConglycinin and Fish Oil. 2018 , 19,	8
131	Management of Nonalcoholic Fatty Liver Disease (NAFLD). 2018 ,	
130	Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2018 , 94, 556-565	11
129	NAFLD and cardiovascular disease. 2018 , 3, e2	2
128	Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease. 2018 , 2018, 4956079	2
127	Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. 2018 , 61, 1923-1934	160
126	An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. 2018 , 23,	16
125	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 7, CD003177	112
124	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 7, CD012345	39
123	Synergistic effect of eicosapentaenoic acid-enriched phospholipids and sea cucumber saponin on orotic acid-induced non-alcoholic fatty liver disease in rats. 2018 , 5, 172182	9
122	Imaging of nonalcoholic fatty liver disease and its clinical utility. 2018 , 17, 69-81	20
121	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. 2018 , 20, 315-329	16
120	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. 2018 , 84, 696-703	6
119	Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. 2018 , 24, 461-474	4
118	Non-Alcoholic Fatty Liver Disease. 2018 , 540-560	

117	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. 2018 , 76, 581-602	49
116	Endogenously increased n-3 PUFA levels in fat-1 transgenic mice do not protect from non-alcoholic steatohepatitis. 2019 , 8, 447-458	2
115	A Lipidomic Analysis of Docosahexaenoic Acid (22:6, ω) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male Mice. <i>Metabolites</i> , 2019 , 9,	5.6 9
114	Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen. 2019 , 13, 30-40	
113	Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. 2019 , 6, 202	55
112	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. 2019 , 103, 28-38	16
111	Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. 2019 , 62, 100-107	15
110	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	15
109	ESPEN guideline on clinical nutrition in liver disease. 2019 , 38, 485-521	202
108	Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. 2019 , 11,	88
107	Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis. 2019 , 423-448	4
106	Past, present and future perspectives in nonalcoholic fatty liver disease. 2019 , 16, 377-386	190
105	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. 2019 , 11,	71
104	What are the main areas of focus to prevent or treat non-alcoholic fatty liver disease?. 2019 , 20, 271-277	2
103	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	1
102	Nonalcoholic Fatty Liver Disease and Obesity Treatment. 2019 , 8, 220-228	34
101	Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. 2019 , 11,	28
100	Nutritional and Dietary Interventions for Nonalcoholic Fatty Liver Disease. 2019 , 357-372	3

99	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. 2019 , 373-389	2
98	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. 2019 , 11,	27
97	Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease. 2019 , 79, 75-84	13
96	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. 2019 , 17, 616-629.e26	53
95	The influence of dietary fatty acids on liver fat content and metabolism. 2020 , 79, 30-41	22
94	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. 2020 , 41,	56
93	High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review. 2020 , 32, 1023-1029	2
92	Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: a systematic review and meta-analysis of randomized controlled trials. 2021 , 60, 2293-2316	11
91	NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. 2020 , 12, 60	104
90	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. 2021 , 50, 101122	23
89	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. 2020 , 111S, 154320	28
88	ESPEN practical guideline: Clinical nutrition in liver disease. 2020 , 39, 3533-3562	52
87	Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. 2020 , 12,	26
86	Metabolic drivers of non-alcoholic fatty liver disease. 2021 , 50, 101143	22
85	Ezetimibe Markedly Reduces Hepatic Triglycerides and Cholesterol in Rats Fed on Fish Oil by Increasing the Expression of Cholesterol Efflux Transporters. 2020 , 374, 175-183	3
84	Discordant Dose-Dependent Metabolic Effects of Eicosapentanoic Acid in Diet-Induced Obese Mice. 2020 , 12,	5
83	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. 2020 , 111S, 154203	46
82	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 513-526	6.1 23

81	The hepatic lipidome: From basic science to clinical translation. 2020 , 159, 180-197	15
80	Improvement in serum lipids and liver morphology after supplementation of the diet with fish oil is more evident under regular feeding conditions than under high-fat or mixed diets in rats. 2020 , 19, 162	4
79	Aging exacerbates high-fat diet-induced steatohepatitis through alteration in hepatic lipid metabolism in mice. 2020 , 35, 1437-1448	6
78	Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. 2020 , 3, CD003177	75
77	Systematic review of marine-derived omega-3 fatty acid supplementation effects on leptin, adiponectin, and the leptin-to-adiponectin ratio. 2021 , 85, 135-152	4
76	Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. 2021 , 218, 135-142	29
75	Nonalcoholic Fatty Liver Disease and Obesity. 2021 , 55, 27-35	0
74	Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. 2021 , 23, 1069-1083	28
73	The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. 2021 , 50, 217-241	2
72	What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. 2021 , 16, e0250385	1
71	Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. 2021 , 14, 837-852	1
70	Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. 2021 , 27, 221-235	7
69	Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2021 , 12, 665987	5-7 2
68	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. 2021 , 22,	17
67	Effect of omega-3 fatty acids supplementation on adipokines: a systematic review and meta-analysis of randomized controlled trials. 2021 , 1-15	2
66	Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. 2021 , 13,	3
65	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
64	Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. <i>Hepatology Communications</i> , 2021 ,	6 1

63	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. 2021 , 27, 363-401	21
62	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. 2021 ,	7
61	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. 2021 , 38, 100997	21
60	Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. 2021 , 43, 1476-1504	5
59	Serum and erythrocyte membrane fatty acid levels may be used as biomarkers to assess the severity of NAFLD. 2021 , 12-22	
58	N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune-Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses. 2021 , 13,	0
57	Proresolving lipid mediators and liver disease. 2021 , 1866, 159023	5
56	Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. 2018 , 11, CD012345	23
55	Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. 2019 , 36, 67-77	3
54	Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. 2016 , 11, e0157580	40
53	Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. 2016 , 11, e0162368	57
52	Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr ^{-/-} mice. 2017 , 12, e0173376	32
51	Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. 2017 , 12, e0189965	22
50	Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. 2021 , 116, 994-1006	6
49	IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). 2019 , 56, 431-439	7
48	Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. 2020 , 27, 5250-5272	26
47	NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. 2017 , 23, 103-108	28
46	The effect of combined diet containing n-3 polyunsaturated fatty acids and silymarin on metabolic syndrome in rats. 2019 , 68, S39-S50	7

45	Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. 2016 , 22, 91-105		19
44	Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?. 2015 , 7, 2184-8		39
43	Management of non-alcoholic fatty liver disease in 2015. 2015 , 7, 2962-7		29
42	Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. <i>ELife</i> , 2020 , 9,	8.9	3
41	Analysis of Mechanistic Pathways in the Treatment of Non-Alcoholic Steatohepatitis. Evidence from a Bayesian Network Meta-Analysis.		0
40	Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. <i>FASEB Journal</i> , 2021 , 35, e21976	0.9	1
39	What is the role of antifibrotic therapies in the current and future management of NAFLD?. 218-225		
38	Nonalcoholic Fatty Liver Disease. 2017 , 199-216		
37	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2018 , 47-69	0	
36	Pathogenetic substantiation of approaches to the treatment of non-alcoholic fatty liver disease.. <i>Klinicheskaia Meditsina</i> , 2018 , 95, 1077-1085	0.2	
35	What influences treatment response in animal models of non-alcoholic fatty liver disease? A meta-analysis with meta-regression.		
34	Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. <i>World Journal of Clinical Cases</i> , 2021 , 9, 9333-9349	1.6	0
33	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. <i>Journal of Clinical and Translational Hepatology</i> , 2021 , 9, 40-50	5.2	4
32	Interplays between nutritional and inflammatory signaling and fat metabolism in pathophysiology of NAFLD. 2020 , 273-295		
31	Advances in the treatment of nonalcoholic steatohepatitis. <i>World Journal of Pharmacology</i> , 2020 , 9, 1-121.8		
30	A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease. <i>Journal of Research in Medical Sciences</i> , 2019 , 24, 21	1.6	4
29	Drugs and Mechanisms Related to the Treatment of Nonalcoholic Fatty Liver Disease. <i>Advances in Clinical Medicine</i> , 2021 , 11, 5237-5244	0	
28	Current and Potential Therapies Targeting Inflammation in NASH.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 767314	5.7	2

27	Quelle alimentation proposer aux patients présentant une stéatohépatite non-alcoolique?. <i>Nutrition Clinique Et Metabolisme</i> , 2022 , 36, 12-20	0.8	0
26	Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.. <i>Hepatology</i> , 2022 ,	11.2	4
25	Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD.. <i>Hepatology Communications</i> , 2022 ,	6	3
24	Histological assessment based on liver biopsy: the value and challenges in NASH drug development.. <i>Acta Pharmacologica Sinica</i> , 2022 ,	8	0
23	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	0
22	A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.. <i>Journal of Hepatology</i> , 2021 ,	13.4	0
21	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. <i>Biomedicines</i> , 2021 , 9,	4.8	1
20	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022 , 12, 433	5.6	1
19	Effect of pharmacological interventions and placebo on liver HISTOLOGY in nonalcoholic steatohepatitis: A network meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022 ,	4.5	0
18	Safety and efficacy of dyslipidemia treatment in NAFLD Patients: a Meta-analysis of randomized controlled trials. <i>Annals of Hepatology</i> , 2022 , 100738	3.1	1
17	Essential lipid autacoids rewire mitochondrial energy efficiency in metabolic dysfunction-associated fatty liver disease. <i>Hepatology</i> ,	11.2	0
16	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint ESPEN/UEG guideline. 2022 ,		4
15	Effects of omega-3 supplementation on serum albumin, pre-albumin and the CRP/albumin ratio in hospitalized patients: a systematic review and meta-analysis.		0
14	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.		1
13	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. 2022 , 211-225		0
12	Therapie: Diät. 2022 , 201-209		0
11	Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. 2022 , 109189		0
10	Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.		0

9	 2023 , 18, 362-380	0
8	AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Publish Ahead of Print,	5
7	Practical Guideline on Obesity care in patients with gastrointestinal and liver diseases [Joint ESPEN / UEG guideline. 2023 ,	0
6	Current Treatment Options, Including Diet, Exercise, and Medications. 2023 , 27, 397-412	0
5	Association between Dietary Fatty Acid Intake and Liver Steatosis and Fibrosis in a Sample of Mexican-Origin Hispanic Adults with Overweight or Obesity. 2023 , 20, 3103	0
4	Nutrition in liver disease. 2023 , 87-134	0
3	The diverse roles of macrophages in metabolic inflammation and its resolution. 11,	0
2	Non-pharmacological management options for MAFLD: a practical guide. 2023 , 14, 204201882311603	0
1	Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review. 2023 , 9, e15347	0